Identification of pre-treatment HBV DNA markers that are predictive of response to lamivudine therapy in patients infected with HBV precore variants.

被引：0
|
作者：
Korba, B
Smedile, A
Rizzetto, M
Lagget, M
Gerin, J
Ciancio, A
机构：
[1] Georgetown Univ, Rockville, MD USA
[2] Osped San Giovanni Battista, Dept Gastroenterol, Turin, Italy
来源：
ANTIVIRAL RESEARCH | 2003年 / 57卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
11
引用
下载
收藏
页码：A43 / A43
页数：1
相关论文
共 50 条
  • [1] Identification of HBV-DNA markers that are predictive of response to lamivudine therapy in patients infected with HBV precore variants
    Ciancio, A
    Smedile, A
    Rizzetto, M
    Lagget, M
    Abate, M
    Gerin, J
    Korba, BE
    JOURNAL OF HEPATOLOGY, 2003, 38 : 134 - 134
  • [2] Evolution of HBV DNA sequences during lamivudine therapy of patients infected with HBV precore variants: Predictors of response?.
    Ciancio, A
    Smedile, A
    Rizzetto, M
    Lagget, M
    Gerin, J
    Korba, B
    HEPATOLOGY, 2002, 36 (04) : 646A - 646A
  • [3] Identification of HBV DNA sequences that are predictive of response to lamivudine therapy
    Ciancio, A
    Smedile, A
    Rizzetto, M
    Lagget, M
    Gerin, J
    Korba, B
    HEPATOLOGY, 2004, 39 (01) : 64 - 73
  • [4] The sequential analysis of the precore region of HBV-DNA during lamivudine therapy in homogeneous patients infected with HBV genotype C in Japan
    Kuwahara, R
    Kumashiro, R
    Murashima, S
    Ogata, K
    Tanaka, K
    Hisamochi, A
    Hino, T
    Ide, T
    Tanaka, E
    Koga, Y
    Sata, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 150 - 150
  • [5] Clinical significance of the analysis of the precore region of HRV-DNA during lamivudine therapy in patients infected with HBV genotype C
    Kuwahara, R
    Kumashiro, R
    Murashima, S
    Ogata, K
    Tanaka, K
    Hisamochi, A
    Hino, T
    Ide, T
    Koga, Y
    Sata, M
    HEPATOLOGY, 2002, 36 (04) : 634A - 634A
  • [6] Pre-treatment and early treatment predictors of eAg clearance in HBV-infected children treated with lamivudine
    Pollack, H
    Hagmann, S
    Neumann, AU
    Chung, M
    Rochford, G
    Lau, C
    Trinh-Sherin, C
    ANTIVIRAL THERAPY, 2002, 7 (04) : L95 - L96
  • [7] Long term lamivudine therapy in patients with precore mutant HBV related liver disease
    Vasiliadis, T
    Patsiaoura, K
    Saveriadis, A
    Kolokotroni, D
    Voutsas, A
    Giouleme, O
    Nikolaidis, N
    Balaska, K
    Orfanou, E
    Evgenidis, N
    JOURNAL OF HEPATOLOGY, 2002, 36 : 172 - 172
  • [8] HBsAg pre-treatment levels and therapy kinetics - marker of HBV viral control in HBV/HIV co-infected patients treated with tenofovir
    Horner, Mary
    Bruce, Matthew J.
    Childs, Kate E.
    Taylor, Chris
    Joshi, Deepak
    Agarwal, Kosh
    Carey, Ivana
    HEPATOLOGY, 2013, 58 : 703A - 703A
  • [9] Therapy with tenofovir in HBV/HIV co-infected patients with resistance or partial response to lamivudine
    Nunez, M
    Garcia-Samantego, J
    Perez-Olmeda, M
    Romero, M
    Rios, P
    Soriano, V
    HEPATOLOGY, 2002, 36 (04) : 636A - 636A
  • [10] Response to lamivudine therapy in children chronically infected with hepatitis B virus (HBV)
    Hagmann, S
    Chung, M
    Rochford, G
    Jani, M
    Sitnitskaya, Y
    Pollack, H
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1161 - 1161
12345